Short answer
Enliven Therapeutics, Inc. (ELVN) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$24M
- +17.2% YoY
- EPS (diluted)
- −$0.38
- +33.3% YoY
Source: XBRL data from the Enliven Therapeutics, Inc. (ELVN) Q1 2026 10-Q on SEC EDGAR. USD.
Enliven Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged year over year; no product sales or other revenue
- Net loss $23.6M vs $28.5M YoY; operating loss $27.8M vs $31.7M
- ELVN-001 R&D expense $7.8M vs $5.0M; ELVN-002 $1.1M vs $8.1M
- Cash, equivalents and marketable securities $452.4M at March 31, 2026; $40.0M gross proceeds from Sales Agreement
- Cash runway at least 12 months; additional funding expected, with development and financing risks ahead
Risk Factors
- ELVN-002 development discontinued while exploring strategic alternatives, concentrating resources on ELVN-001 and its upcoming pivotal trial
- Net loss $23.6 million for the quarter and accumulated deficit $370.8 million as of March 31, 2026
- FDA comparability review risk for alternative ELVN-001 tablet formulations, potentially requiring bridging studies
- ELVN-001 remains in Phase 1 for CML, making clinical failure or delay the primary near-term operating risk
- Additional capital required to complete development, with financing constraints potentially forcing program reductions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Enliven Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.